Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial

Manish A. Shah(NewYork–Presbyterian Hospital), Rui‐Hua Xu(Sun Yat-sen University), Ahsan M. Arozullah(Astellas Pharma (United States)), Javier Gállego(Hospital General Universitario de Elche), Lin Shen(Peking University), David H. Ilson(Memorial Sloan Kettering Cancer Center), Jaffer A. Ajani(The University of Texas MD Anderson Cancer Center), Florian Lordick(Leipzig University), Yung‐Jue Bang(Seoul National University), Patrapim Sunpaweravong(Prince of Songkla University), Pranob Bhattacharya(Astellas Pharma (United States)), Sang Cheul Oh(Korea University), Diarmuid Moran(Astellas Pharma (United States)), Hacı Mehmet Türk(Bezmiâlem Vakıf Üniversitesi), Mok Oh(Astellas Pharma (United States)), Peter C. Enzinger(Dana-Farber Cancer Institute), Eric Van Cutsem(Universitair Ziekenhuis Leuven), Jing Huang(Chinese Academy of Medical Sciences & Peking Union Medical College), Kohei Shitara(National Cancer Center Hospital East), Jung Wook Park(University of California, Los Angeles), Hwoei Fen Soo Hoo(Penang Adventist Hospital)
Nature Medicine
July 31, 2023
10.1038/s41591-023-02465-7
Cited by 541

Related Papers

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
|New England Journal of Medicine|2009|8.2k
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
|The Lancet|2010|7.3k
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
Gastric cancer
|The Lancet|2020|4.8k
Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors
|New England Journal of Medicine|2017|3.2k